Normal cells with intact type I interferon response

Normal cells with intact type I interferon response refers to healthy, non-transformed cells that maintain a fully functional innate immune signaling pathway triggered by type I interferons, primarily IFN-alpha and IFN-beta (Source: NIH/NCBI, 'The type I interferon system'). Upon viral infection or exposure to IFN, these cells activate the JAK-STAT pathway, resulting in the transcription of hundreds of interferon-stimulated genes (ISGs) such as MX1 and OAS1 that establish an antiviral state, effectively halting viral replication and protein synthesis (Source: Nature Reviews Immunology, 'Type I interferon in health and disease'). This physiological state is a cornerstone of therapeutic selectivity in oncolytic virology, where viruses like Talimogene laherparepvec are engineered to replicate specifically in cancer cells that have acquired defects in their IFN response to evade immune surveillance (Source: Nature Reviews Cancer, 'Oncolytic viruses: a new class of cancer immunotherapy'). In these therapies, the intact IFN response in normal cells acts as a natural defense mechanism, preventing off-target viral toxicity and ensuring that the treatment remains localized to the tumor microenvironment. Consequently, this 'target' is not a single molecule but a critical biological context used to evaluate the safety and therapeutic index of immunotherapies and viral vectors.

Other names

IFN-competent cellsHealthy cells with functional IFN signalingType I IFN-responsive cellsNon-malignant cells with intact antiviral response

Activation of the JAK-STAT signaling pathway leading to the expression of interferon-stimulated genes (ISGs) that inhibit viral replication and protein synthesis.